GlassScriptPhysician profile
Danielle A Becker
NPI 1134381759
$1,588,497.34
in general payments reported to CMS, 2019-2025
17 companies · $340K in 2025
The $340K reported for 2025 was more than what 99% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $101K · 2021: $165K · 2022: $304K · 2023: $302K · 2024: $363K · 2025: $340K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550K · Honoraria: $258K · Travel and Lodging: $108K · Consulting Fee: $66K · Food and Beverage: $23K · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $549,766.14 |
| Honoraria | $258,100.00 |
| Travel and Lodging | $108,009.69 |
| Consulting Fee | $65,505.30 |
| Food and Beverage | $22,938.26 |
| Education | $108.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $555,425.95 | 2020-2025 | Xcopri |
| Neurelis, INC. | $390,219.65 | 2020-2025 | Valtoco |
| Livanova USA, INC. | $370,972.24 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Jazz Pharmaceuticals INC. | $156,794.89 | 2022-2025 | |
| Neuropace, INC. | $80,015.85 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $16,172.26 | 2019-2021 | |
| Ucb, INC. | $13,677.36 | 2019-2023 | Briviact |
| Eisai INC. | $3,360.00 | 2020 | |
| Antares Pharma, INC. | $600.00 | 2020 | |
| Horizon Therapeutics Plc | $493.49 | 2021 | |
| Greenwich Biosciences, INC. | $293.10 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $290.00 | 2019 | |
| Servier Pharmaceuticals LLC | $99.75 | 2025 | |
| Medtronic USA, INC. | $36.78 | 2019 | |
| Tg Therapeutics, INC. | $16.17 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $15.85 | 2025 | Ztalmy |
| Catalyst Pharmaceuticals, INC. | $14.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.